Navigation Links
XTENT Announces Clinical Trial Data to be Presented at Annual EuroPCR Meeting Next Week
Date:5/7/2008

Webcast to Review CUSTOM III Six-Month Data to be held Tuesday, May 13th

MENLO PARK, Calif., May 7 /PRNewswire-FirstCall/ -- XTENT, Inc. (Nasdaq: XTNT) today announced that six-month follow-up data from the CUSTOM III trial will be presented at EuroPCR, taking place May 13 to 16 in Barcelona. The company will hold a webcast and conference call to review the new CUSTOM III data immediately following the late-breaking session. In addition, two-year CUSTOM I data, previously presented at the Transcatheter Cardiovascular Therapeutics (TCT) meeting last October, has been accepted for publication in the May issue of EuroIntervention. Professor Grube, the CUSTOM I principal investigator, has been asked to present the data during a EuroPCR session on the six best papers from EuroIntervention. XTENT is also sponsoring an evening symposium on customizable drug-eluting stents and will exhibit throughout the meeting at booth E11 in the main hall.

Schedule of XTENT Events for EuroPCR

Tuesday, May 13, 2008, 3:30-6:30 p.m. CEST, Room 1

Late-Breaking Clinical Trial: CUSTOM III trial 6-month follow-up results.

Bernard de Bruyne, M.D., Ph.D, Cardiovascular Center, OLV Hospital in Aalst, Belgium, the principal investigator of the CUSTOM III clinical trial, will present six-month follow-up data from the CUSTOM III trial evaluating use of the Custom NX(R) Drug Eluting Stent (DES) System in patients with long or multiple coronary lesions.

Tuesday, May 13, 2008, 7:00 p.m. CEST (1:00 p.m. EDT)

CUSTOM III webcast and conference call.

To participate in the conference call, please dial 877-591-4957 (from the U.S.) or 719-325-4895 (international). The webcast and slide presentation can be accessed via the investor relations section of the Company's website at http://investor.xtentinc.com/events.cfm. Please dial in or access the website five to 10 minutes prior to the beginning of the call. If you do dial-in, please also view the slides via the webcast. The webcast will be archived on the website for a minimum of three months, and can be accessed at the investor relations portion of the company's website at http://investor.xtentinc.com

Wednesday, May 14, 2008, 5:00-6:30 p.m. CEST, Room 5

Evening symposium: Customizable drug-eluting stents: a breakthrough approach to the percutaneous treatment of coronary artery disease.

The symposium will provide an overview of the Custom NX DES System with respect to the treatment of long and multi-lesion coronary artery disease, and the CUSTOM clinical program.

Thursday, May 15 12:00-1:30 pm CEST, Room 122/123

EuroIntervention @ EuroPCR: CUSTOM I two-year follow-up results

Eberhard Grube, M.D., Chief of Cardiology at the HELIOS Heart Center in Siegburg, Germany, the principal investigator of the CUSTOM I clinical trial, will present two year follow-up data from the CUSTOM I trial.

About the Custom NX(R) DES System

Custom NX is designed to enable a more personalized approach to the treatment of arterial disease based on each patient's individual lesion characteristics. The Custom NX system allows physicians to customize the length and diameter of the stent at the site of the lesion. The system features a proprietary modular stent design that consists of multiple 6mm cobalt chromium segments coated with Biolimus A9(R) and PLA, a biodegradable drug carrier. The Custom NX delivery system enables separation at each 6mm segment and allows for the placement of up to 60mm of stent.

About XTENT

XTENT, Inc. is a medical device company focused on developing and commercializing innovative customizable drug eluting stent (DES) systems for the treatment of coronary artery disease (CAD). CAD is the most common form of cardiovascular disease and the number one cause of death in the United States and Europe. XTENT(R) Custom NX(R) DES Systems are designed to enable the treatment of single lesions, long lesions and multiple lesions of varying lengths and diameters, in one or more arteries with a single device. Note: XTENT(R) Custom NX(R) DES Systems have not been approved for sale by any regulatory authority.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this press release regarding XTENT's business that are not historical facts may be "forward-looking statements" that involve risks and uncertainties. Specifically, these statements include, but are not limited to those concerning: XTENT's expectations with respect to the timing of the release of its clinical trial data. Forward-looking statements are based on management's current, preliminary expectations, and are subject to risks and uncertainties that could cause actual results to differ from the results predicted and which are included in the "Risk Factors" section of XTENT's annual report on Form 10-K for the year ended December 31, 2007. This annual report was filed with the SEC on March 17, 2008, and is available on the company's investor relations website at http://www.xtentinc.com and on the SEC's website at http://www.sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. XTENT undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.

http://www.xtentinc.com


'/>"/>
SOURCE XTENT, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. XTENT to Present CUSTOM I and CUSTOM II Trial Data at TCT 2007
2. XTENT Announces Positive Two-Year CUSTOM I and One-Year CUSTOM II Trial Data for Novel Drug-Eluting Stent System
3. Study Data Show Asacol(R) (Mesalamine) is Effective in Treating All Extents of Ulcerative Colitis Including Isolated Proctitis
4. XTENT Announces First Quarter 2008 Financial Results
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... -- AfterPill.com is reporting that this week,s Centers for Disease ... who are at risk of unintended pregnancy impacts 43 ... the risks of unprotected sex in particular.  ... the Guttmacher Institute, there are 43 million women in ... have sex without the intention of becoming pregnant.  Despite ...
(Date:2/11/2016)... , 11 de fevereiro de 2016 /PRNewswire/ ... de sua fábrica de soroalbumina bovina (BSA -- ... A fábrica fica na Ilha Norte da Nova ... desenvolvido e estabelecido na fábrica da Proliant nos ... . O projeto e instalação dos equipamentos foram ...
(Date:2/11/2016)... ROLLING MEADOWS , Ill. and INDIANAPOLIS ... major milestone for many young people, but for those ... demanding. Not only do these students juggle class schedules, ... challenges of living with type 1 diabetes. On top ... the first time. Diabetes Scholars Foundation ...
Breaking Medicine Technology:
(Date:2/12/2016)... Pittsburgh, PA (PRWEB) , ... February 12, 2016 ... ... serving families of the Pittsburgh metro area, celebrates the beginning of the latest ... help children develop social skills through art. Donations to this worthy cause are ...
(Date:2/12/2016)... ... February 12, 2016 , ... Mediaplanet today ... , The print component of “Revolutionizing Cancer Care” is distributed within the February ... and Seattle, with a circulation of approximately 250,000 copies and an estimated readership ...
(Date:2/12/2016)... ... February 12, 2016 , ... A lot has been reported about ... president has access to health and wellness resources most Americans could ever dream of ... individual has a schedule as frenetic as the U.S. President. , In honor ...
(Date:2/12/2016)... ... , ... Basketball is a game for everyone, not just those who can ... language translation is featured in the top right of the screen. Every technique that ... a sign language translator to teach kids the game and how to be as ...
(Date:2/11/2016)... ... February 11, 2016 , ... “ HEALING MIND : ... Well Managed Mind” (published by Balboa Press) teaches readers how to become their own ... profound love, author Janice McDermott, M.Ed., LCSW, offers an understanding of how to heal ...
Breaking Medicine News(10 mins):